Discussion should cover injection technique, adverse effect management, cost considerations (often $900-1,300 monthly without insurance coverage), and long-term treatment duration, as weight regain commonly occurs after discontinuation
For weight management , semaglutide (Wegovy) is approved by the MHRA and has received a positive NICE technology appraisal recommendation for use in adults with obesity or overweight with weight-related comorbidities, subject to eligibility criteria
HGF/c-Met signaling is a well-established oncogenic pathway: c-Met is amplified or overexpressed in multiple cancers (gastric, lung, renal, hepatocellular) HGF/c-Met activation promotes tumor cell proliferation, survival, invasion, and metastasis c-Met inhibitors are FDA-approved cancer drugs (cabozantinib, crizotinib, capmatinib) A compound that potentiates HGF/c-Met signaling raises theoretical concerns about promoting tumor growth or transformation with chronic use
Creatine increases creatinine levelsa waste product that kidneys filterwhile semaglutide can cause dehydration and osmotic shifts that temporarily stress renal function
